Stryker, a global provider of medical technologies, has introduced its latest advancements in Mako SmartRobotics at the American Academy of Orthopaedic Surgeons (AAOS) 2025 Annual Meeting in San Diego.
The advancements are designed to enhance surgical precision, improve patient outcomes, and streamline workflow for orthopedic procedures, particularly across hip, knee, spine, and shoulder procedures.
Stryker has expanded its Mako Total Hip by featuring it with Advanced Primary and Revision, bringing a first-to-market robotic hip revision capability, which is particularly significant for revision total hip arthroplasty.
In revision total hip arthroplasty (THA), the enhanced Mako Total Hip application is designed to streamline workflow and increase surgical confidence with new features, such as augment and screw planning, intra-operative screw trajectory guidance, and compatibility with Stryker’s revision hip implant portfolio.
Moreover, the compatibility with Stryker’s revision hip implant portfolio further solidifies the Mako system as a comprehensive solution for both primary and revision THA. The capacity to leverage 3D CT-based planning across both procedure types empowers surgeons with enhanced pre-operative insight and facilitates more precise execution.
In addition to these advancements, the giant medical provider also has launched its fourth-generation Mako System, Mako 4, a cutting-edge robotics platform that consolidates multiple applications into a single system.
The single robotics system delivers additional applications, designed to deliver a clinical and operational experience across Mako Total Hip, Total Knee, Partial Knee, and Spine, offering significant improvements over traditional manual techniques. It also integrates Stryker’s fourth-generation Q Guidance System.
Furthermore, the company is also expanding the SmartRobotics suite with the addition of Mako Spine and Mako Shoulder. While still in a limited market release, the successful completion of initial cases suggests promising potential for these applications.
Stryker successfully completed its first Mako Spine procedures in October 2024 and is currently in a limited market release phase, with a full U.S. commercial launch expected in the second half of this year.
Meanwhile, Mako Shoulder completed its first case at the end of last year and will remain in limited market release throughout 2025. Both these applications received FDA nods last year.
Keith Evans, vice president and general manager of Stryker’s Mako and Enabling Technologies business, envisions the future of Mako, which is to serve a broader spectrum of surgeons, patients, specialties, and procedures.
